Skip to content

GU Cancers 

US Focus Meeting 2026

📍 Hyatt Regency Boston Harbor, 101 Harborside Dr, Boston, MA 02128

🗓️ August 14 - 15, 2026

Dear Colleagues and Friends,

We are delighted to extend our warmest invitation to the GU Cancers Focus Meeting 2026, to be held at on August 14 - 15, 2026.  

Centered around the theme “Updating Knowledge & Clinical Practice in 2026” this meeting provides pivotal collaboration aimed at advancing GU Cancers research and patient treatment.  

This meeting presents an opportunity for medical professionals to engage in the exchange of knowledge, expertise, and insights, as well as networking with leading experts. Engage in riveting presentations, participate in thought-provoking debates and roundtable discussions, and connect with peers at informal social gatherings.

Chairs of GU Cancers US Focus Meeting 2026:

Toni-Choueiri

Toni Choueiri, MD
Dana-Farber Cancer Institute, Boston, MA


Rana_McKay

Rana R. McKay, MD
UC San Diego, CA


Supporters to be announced...
Interested in supporting this meeting? Get in contact:
aimee.williams@md-education.com

Agenda & Faculty

August 14, 2026 | Day 1

07:00 AM
Registration Opens
08:00 AM
Industry Supported Independent Expert Discussion
08:45 AM
Coffee Break

Session I: Initial Systemic Treatment in RCC
Moderated by:

Michael-Serzan

Michael Serzan, MD
Dana-Farber Cancer Institute, Boston, MA

09:05 AM
Adjuvant Immunotherapy: Patient Selection and Implementation
Bradley-McGregor
Bradley McGregor, MD
Dana-Farber Cancer Institute, Boston, MA
09:20 AM
IO Combination Strategies in Clear Cell RCC
Wenxin-Xu
Wenxin Xu, MD
Dana-Farber Cancer Institute, Boston, MA
09:35 AM
Systemic Treatment Approaches for Variant Histologies
Sumanta-Pal
Sumanta Pal, MD
City of Hope, Duarte, CA
09:50 AM
Case Discussion: Adjuvant IO Failure and Progression
Michael-Serzan
Michael Serzan, MD
Dana-Farber Cancer Institute, Boston, MA
10:05 AM
Panel Discussion
10:20 AM
Coffee Break

Session II: Post-Progression Treatment of Advanced RCC
Moderated by:

Xin-Gao

Xin Gao, MD
Massachusetts General Hospital, Boston, MA

10:40 AM
HIF2α Inhibition in RCC
Yu_Wei-Chen
Yu-Wei Chen, MD
UC San Diego Health, CA
10:55 AM
VEGF TKI Selection and Sequencing

TH

Thai Huu Ho, MD
MUSC Health, Charleston, SC
11:10 AM
Toxicity Management: IO, VEGF, and HIF Inhibitors
Stephanie-Berg
Stephanie Berg, MD
Dana-Farber Cancer Institute, Boston, MA
11:25 AM
Case Discussion: Treatment Options After IO and VEGF Failure
Xin-Gao
Xin Gao, MD
Massachusetts General Hospital, Boston, MA
11:40 AM
Panel Discussion
11:55 AM
Lunch Break + Faculty and Fellow Photo
12:55 AM
Industry Supported Independent Expert Discussion

Session III: Perioperative Management of Muscle-Invasive Bladder Cancer
Moderated by:

Alexandra-Drakaki

Alexandra Drakaki, MD
UCLA Health, Los Angeles, CA

01:40 PM
Bladder-Sparing Treatment Approaches
Kent-Mouw
Kent Mouw, MD
Dana-Farber Cancer Institute, Boston, MA
01:55 PM
Perioperative Immunotherapy Integration
Joaquim-Bellmunt
Joaquim Bellmunt, MD
Dana-Farber Cancer Institute, Boston, MA
02:10 PM
ctDNA in Perioperative Bladder Cancer
Matthew-Galsky
Matthew Galsky, MD
Icahn School of Medicine at Mount Sinai, New York, NY
02:25 PM
Case Discussion: T3 MIBC with Positive ctDNA After Treatment
Alexandra-Drakaki
Alexandra Drakaki, MD
UCLA Health, Los Angeles, CA
02:40 PM
Panel Discussion
02:55 PM
Coffee Break
03:15 PM
Industry Supported Independent Expert Discussion

Session IV: Treatment Strategies of Metastatic Urothelial Cancer Treatment
Moderated by:

Guru-Sonpavde

Guru Sonpavde, MD
Advent Health Cancer Institute, Orlando, FL

04:00 PM
First-Line Treatment Selection: Chemo vs IO vs Maintenance
Jonathan-Rosenberg
Jonathan Rosenberg, MD
Memorial Sloan Kettering Cancer Center, New York, NY
04:15 PM
Molecular Testing and Targeted Therapy Implementation
Abhishek-Tripath
Abhishek Tripathi, MD
City of Hope, Duarte, CA
04:30 PM
ADC and Targeted Therapy Toxicity Management
Charlene-Mantia
Charlene Mantia, MD
Dana-Farber Cancer Institute, Boston, MA
04:45 PM
Case Discussion: HER2+ Metastatic Disease Treatment Decisions
Guru-Sonpavde
Guru Sonpavde, MD
Advent Health Cancer Institute, Orlando, FL
05:00 PM
Panel Discussion
05:15 PM
Closing Remarks
05:25 PM
Adjourn

August 15, 2026 | Day 2

07:00 AM
Registration Opens
08:00 AM
Industry Supported Independent Expert Discussion
08:45 AM
Approach to Biochemical Recurrent Prostate Cancer

Session V: Approach to Biochemical Recurrent Prostate Cancer
Moderated by:

David-Einstein

David Einstein, MD
Beth Israel Deaconess Medical Center, Boston, MA

09:05 AM
PSMA PET Imaging and Oligometastatic Treatment
Tyler-Seibert
Tyler Seibert, MD
UC San Diego Health, CA
09:20 AM
High-Risk BCR: Definition and Treatment Approaches
Michael-Hurwitz
Michael Hurwitz, MD
Yale School of Medicine, New Haven, CT
09:35 AM
Systemic Treatment Approaches for Variant Histologies
Matthew-Smith
Matthew Smith, MD
Massachusetts General Hospital, Boston, MA
09:50 AM
Case Discussion: Oligometastatic BCR Treatment Selection
David-Einstein
David Einstein, MD
Beth Israel Deaconess Medical Center, Boston, MA
10:05 AM
Panel Discussion
10:20 AM
Coffee Break

Session VI: Management of Metastatic Hormone-Sensitive Prostate Cancer
Moderated by:

Phillip-Saylor

Philip Saylor, MD
Massachusetts General Hospital, Boston, MA

10:40 AM
Triple Therapy: Evidence and Implementation
David-Wise
David Wise, MD
NYU Langone Medical Center, New York, NY
10:55 AM
Novel Triple Combinations: PARP, PSMA, and AKT Inhibitors
Praful-Ravi
Praful Ravi, MD
Dana-Farber Cancer Institute, Boston, MA
11:10 AM
ARSI Selection: Factors for Agent Choice
Alicia-Morgans
Alicia Morgans, MD
Dana-Farber Cancer Institute, Boston, MA
11:25 AM
Case Discussion: De Novo High Volume mHSPC with Adverse Genetics
Phillip-Saylor
Philip Saylor, MD
Massachusetts General Hospital, Boston, MA
11:40 AM
Panel Discussion
11:55 AM
Lunch Break + Faculty and Fellow Photo
12:55 AM
Industry Supported Independent Expert Discussion

Session VII: Treatment Strategies for Metastatic Castration-Resistant Prostate Cancer
Moderated by:

Mark-Stein

Mark Stein, MD
Columbia University Irving Medical Center, New York, NY

01:40 PM
Radiopharmaceutical Integration
Oliver-Sartor
Oliver Sartor, MD
Tulane University School of Medicine, New Orleans, LA
01:55 PM
Genetic Testing and PARP Inhibitor Treatment
Alok-Tewari
Alok Tewari, MD
Dana-Farber Cancer Institute, Boston, MA
2:10 PM
Neuroendocrine Prostate Cancer: Recognition and Treatment
Himisha-Beltran
Himisha Beltran, MD
Dana-Farber Cancer Institute, Boston, MA
2:25 PM
Case Discussion: mCRPC Treatment Sequencing Decisions
Mark-Stein
Mark Stein, MD
Columbia University Irving Medical Center, New York, NY
02:40 PM
Panel Discussion
02:55 PM
Coffee Break
03:15 PM
Industry Supported Independent Expert Discussion

Session VIII: Novel Therapeutics in Genitourinary Cancers
Moderated by:

Cathy-Eng

Daniel George, MD
Duke Health, Durham, NC

04:00 PM
Novel Agents in RCC
David-Braun
David Braun, MD
Yale School of Medicine, New Haven, CT
04:15 PM
Emerging Targeting in Urothelial Carcinoma
Vadim-Koshkin
Vadim Koshkin, MD
UCSF Health, San Francisco, CA
04:30 PM
Next Generation Treatments in Prostate Cancer
Atish-Choudhury
Atish Choudhury, MD
Dana-Farber Cancer Institute, Boston, MA
04:45 PM
Case Discussion: Clinical Trial Enrollment and Patient Experience
Daniel-George
Daniel George, MD
Duke Health, Durham, NC
05:00 PM
Panel Discussion
05:15 PM
Closing Remarks
05:25 PM
Adjourn

Aimee Williams
Project Manager

How long has Aimee Williams been in the business?

Aimee Williams has been with MD Education since 2022

About Aimee Williams

I joined MD Education in 2022 as a Project Manager, leveraging my background in events management and passion for high-quality results. After earning a degree in Events Management, I gained hands-on experience managing projects while living in Nashville, TN. Driven and detail-oriented, I thrive in fast-paced environments, ensuring projects meet the highest standards. An avid traveler, I bring creativity and open-mindedness to problem-solving and client relationships.

Screenshot 2026-01-20 at 11.18.20